Sinclair Pharma to report strong revenue growth
This article was originally published in Scrip
Executive Summary
Sinclair Pharma is expected to post revenues of £30.2 million in preliminary financial results for the year ended June 30th. This is an increase of 30% compared with the same period last year, Piper Jaffray analysts say. A trading update at the end of July indicated that growth occurred across all of the company's major markets, especially in the dermacosmetics field. The analysts have estimated that Sinclair will benefit from a positive currency effect of £1.2 million and licence fee income of £1 million from the relicensing of the mouth ulcer treatment Aloclair following a change in its agreement with Sunstar Butler. In the results, which will be announced on October 1st, Piper Jaffray believes Sinclair will report maiden profitability for the full year. In addition, the company is expected to report net debt of £2.9 million, which should be supplemented by a €2.2 million exceptional tax repayment from the French tax authorities next month, Piper Jaffray add.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.